Following Pfizer''s announcement last month that it has agreed to acquire rival big pharma Pharmacia, Oxford GlycoSciences chief financial officer Stephen Parker said last week that his company is holding out hope that its proteomics relationship with Pfizer emerges unscathed.
"At the moment at least, it doesn''t seem to be getting in the way," he told ProteoMonitor in reference to Pfizer''s pending acquisition. "Amazingly, they don''t even seem to be distracted."
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
